EUVIMEDEUVIMED entdecken
Leserbrief

Global Clinical Trial Landscape of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Where Are We Headed?

K Luo, S Liu, Y Liu

Clinical Oncology · 2026-06 · 54 · 104157

DOI: 10.1016/j.clon.2026.104157 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Clinical Oncology, 2026-06. Verfasst von K Luo und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, Shaanxi Province, China. Electronic a…. Die Arbeit nennt 5 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, Shaanxi Province, China. Electronic address: josephkay@foxmail.com.
  • Department of Otorhinolaryngology Head and Neck Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
  • The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, Shaanxi Province, China.

Zitieren

APA

Luo, K., Liu, S., & Liu, Y. (2026). Global Clinical Trial Landscape of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Where Are We Headed?. Clinical Oncology, 54, 104157. https://doi.org/10.1016/j.clon.2026.104157

Vancouver

Luo K, Liu S, Liu Y. Global Clinical Trial Landscape of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Where Are We Headed?. Clinical Oncology. 2026;54:104157. doi:10.1016/j.clon.2026.104157

BibTeX
@article{Luo2026,
  author = {Luo, K and Liu, S and Liu, Y},
  title = {Global Clinical Trial Landscape of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Where Are We Headed?},
  journal = {Clinical Oncology},
  year = {2026},
  volume = {54},
  pages = {104157},
  doi = {10.1016/j.clon.2026.104157}
}
Kostenlos starten →